Search Results
Sep 10, 2026, 08:49 ET GBI Bio Appoints Jesse McCool, Ph.D., as Chief Executive Officer
GBI's identity over its thirty-four-year history. Driving this is the company's investment in SmartScale™ GMP, the industry's first ever integrated CMC platform designed to accelerate the progression of early-stage biologics from gene to
More news about: GBI Biomanufacturing
Sep 09, 2026, 08:00 ET Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta's strategic partner for CMC development and supporting molecules across Transcenta's development pipeline. HiCB platform integrates intensified continuous perfusion upstream
More news about: Transcenta Therapeutics
Sep 08, 2026, 09:18 ET Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Scinai has commenced substantive activities on the previously disclosed expanded clinical manufacturing and chemistry, manufacturing and controls ("CMC") program for a U.S.-based biopharmaceutical customer. The program is intended to support a planned U.S. regulatory submission and subsequent Phase
More news about: Scinai Immunotherapeutics Ltd.
Sep 08, 2026, 06:59 ET Carboxymethylcellulose Calcium Market worth $0.09 billion by 2036 - Exclusive Report by MarketsandMarkets™
production, particularly in emerging markets, is expected to increase demand for high-purity pharmaceutical excipients. In addition, pharmaceutical-grade CMC calcium must meet stringent pharmacopeial specifications, which supports its use in regulated drug formulations and creates higher-value demand compared
More news about: MarketsandMarkets
Sep 03, 2026, 15:06 ET SoulFIRE Leadership, LLC Announces New Book and Leadership Model for Senior Women in Finance and Tech
Executive coach, author, and speaker Amanda L. Christian, CMC, IGNLP, argues that the convergence raises a question that representation numbers alone do not answer: If more women are reaching positions of influence,
More news about: SoulFIRE Leadership, LLC
Sep 02, 2026, 23:26 ET 亞洲生技大會台康生物藥開發平臺吸睛，劉理成談 CDMO 該往何方
DNA等產品；相較之下，哺乳類細胞則能提供更接近人體的蛋白質後轉譯修飾（Post-translational Modifications），並且可以執行完整之「醣基化作用 (glycosylation)」，尤其適用於單株抗體、雙特異性抗體、抗體藥物複合體等複雜生物藥的生產。但劉理成也強調兩者並非孰優孰劣，而是依據分子特性、產品需求及後續 CMC 規劃，來選擇最適合的表現系統。而若將今年台康 Mini Talks 系列串聯起來，則可發現各主題其實圍繞著同一個核心問題：如何降低生物藥開發的不確定性。先進療法、AI、CDMO 將成下一波成長關鍵不只從企業經營角度觀察生物藥產業發展與技術演進，身兼本次亞洲生技大會主辦單位台灣生物產業發展協會理事長的他，也從今年大會的國際交流中，看見全球生技產業正加速朝先進療法、AI
More news about: 基因線上
Sep 02, 2026, 09:00 ET CMC Bottleneck is Choking Biopharma's Drug Pipeline, says Zifo
pass through Chemistry, Manufacturing and Controls, or CMC. And that pathway is struggling to keep pace.In its new position paper, "The Billion-Dollar Bottleneck: Why CMC is Strangling the Biopharma Pipeline," Zifo argues that CMC has become one of the industry's most consequential operational
More news about: Zifo
Sep 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for September 2026
OperationsPHARMA MANUFACTURING & SUPPLY CHAINSep 8 - Improve Drug Solubility from Formulation to Scale-UpSep 10 - CMC Strategy in Biologics: Decisions With Downstream ConsequencesSep 17 - Expand Bispecific Purification Strategies Beyond mAb PlatformsSep
More news about: Xtalks
Sep 01, 2026, 09:00 ET Tripo AI Raises 3 Billion Yuan in Series B and Series B+ Funding
ThunderSoft, and 37 Interactive Entertainment. The financing rounds were also backed by financial investors such as CDH Venture and Growth Capital, CICC, CMC Capital Partners, Hongtai Aplus, 3H Health, Zhongping Capital, and GreatOrigin Asia. Existing investors Fortune Capital, Primavera Capital, 4399 Network,
More news about: Tripo AI
Sep 01, 2026, 08:45 ET Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2016 Pharmaceutical Quality/CMCForward-Looking StatementsAll statements contained in this press release, other than statements of historical fact, including,
More news about: Devonian Health Group Inc.
Aug 31, 2026, 10:25 ET Steel Rebar Market to Reach 201.56 Million Tons by 2031 as Infrastructure Spending and Low-Carbon Steelmaking Drive Demand, Reports Mordor Intelligence
Steel Rebar CompaniesArcelorMittalCMC (Commercial Metals Company)Daido Steel Co., Ltd.EMSTEELGerdau S/AHybar LLCHyundai SteelJFE Steel
More news about: Mordor Intelligence Private Limited
Aug 27, 2026, 09:31 ET Outdoo AI Named #1 AI Sales Roleplay Platform for Best Results & Most Implementable on G2
it pays off.Outdoo AI is trusted by Fortune 500 organizations across regulated, high-consequence industries, including Globe Life Insurance, CMC, Sage, Wolters Kluwer, Keller Williams, Qure.ai, RAIN Group, Tensar, Providesure, and Sigvaris Group, where reps need to be ready for real conversations,
More news about: Outdoo AI
Aug 27, 2026, 07:32 ET African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
candidates and scalable manufacturing," said Dr Volker Sandig, Chief Scientific Officer of ProBioGen. "We are proud to bring this platform and our CMC expertise to a Minapharm-led programme supported by CEPI, helping advance a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation in response
More news about: Minapharm Pharmaceuticals
Aug 27, 2026, 07:27 ET African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
candidates and scalable manufacturing," said Dr Volker Sandig, Chief Scientific Officer of ProBioGen. "We are proud to bring this platform and our CMC expertise to a Minapharm-led programme supported by CEPI, helping advance a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation in response
More news about: Minapharm Pharmaceuticals
Aug 27, 2026, 06:45 ET CMC Named to Newsweek's America's Greatest Companies 2026 List
accomplished and remain focused on executing our strategy, serving our customers and building an even stronger, more sustainable CMC for the future."About CMCCMC is a Fortune 500® company headquartered in Irving, Texas, and a leading provider of early-stage construction
More news about: CMC
Aug 26, 2026, 23:09 ET Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves ProfitabilityDuring the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment and optimization of its client portfolio, the CMC business has continuously improved
More news about: Viva Biotech
Aug 26, 2026, 10:57 ET Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves ProfitabilityDuring the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment and optimization of its client portfolio, the CMC business has continuously improved
More news about: Viva Biotech
Aug 26, 2026, 06:47 ET Alebund Pharmaceuticals Announces 2026 Interim Results
the global Phase IIb multi-regional clinical trial of AP306, and the continued advancement of preclinical and chemistry, manufacturing, and controls (CMC) studies of AP308.Liquidity. As of June 30, 2026, the aggregate balance of cash and cash equivalents, time deposits, and wealth management
More news about: Alebund Pharmaceuticals
Aug 25, 2026, 09:00 ET Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa
The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activitiesApproximately 94% of existing investors participated in the Series E-2 roundInterim analysis completing the Phase
More news about: Airway Therapeutics
Aug 25, 2026, 09:00 ET Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa
The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activitiesApproximately 94% of existing investors participated in the Series E-2 roundInterim analysis completing the Phase
More news about: Airway Therapeutics
Aug 25, 2026, 09:00 ET Airway Therapeutics schließt eine Finanzierungsrunde in Höhe von 50 Millionen US-Dollar ab, um die Entwicklung von Zelpultide Alfa in der späten Phase voranzutreiben
Kapitalerhöhung dient der Finanzierung der laufenden klinischen Studie der Phase 2b/3 zur Prävention der bronchopulmonalen Dysplasie sowie der damit verbundenen CMC- und analytischen AktivitätenRund 94 % der bestehenden Investoren beteiligten sich an der Finanzierungsrunde der Serie E-2Eine Zwischenanalyse
More news about: Airway Therapeutics
Aug 25, 2026, 09:00 ET Airway Therapeutics clôture un tour de table de 50 millions de dollars pour faire avancer le développement en phase avancée du zelpultide alfa
fonds soutient l'essai clinique de phase 2b/3 en cours visant à prévenir la dysplasie bronchopulmonaire, ainsi que les activités associées en matière de CMC et d'analyse.Environ 94 % des investisseurs existants ont participé au tour de table de série E-2Une analyse intermédiaire clôturant
More news about: Airway Therapeutics
Aug 25, 2026, 09:00 ET Airway Therapeutics cierra una financiación de 50 millones de dólares para el desarrollo de Zelpultide Alfa
alfa para la prevención de la displasia broncopulmonar (BPD) en bebés muy prematuros, así como a las actividades de química, fabricación y control (CMC) y analíticas necesarias para el avance del programa.La ronda Serie E-2 contó con una amplia participación de la base de inversores de Airway,
More news about: Airway Therapeutics
Aug 24, 2026, 07:00 ET Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
of August 16, 2026, of which approximately $2.1 million had been invoiced.The Company is progressing an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company building on an existing contractual relationship and prior work performed through the customer's affiliate.Approximately
More news about: Scinai Immunotherapeutics Ltd.
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
(CDH17 ADC), with plans to submit Investigational New Drug (IND) applications for these candidates in the second half of 2026. By leveraging its robust CMC capabilities, the company is further increasing the probability of success in developing complex molecules, thereby enhancing overall drug developability.
More news about: Henlius